Integration-free induced pluripotent stem cells model genetic and neural developmental features of down syndrome etiology

Stem Cells

Volumn 31, Issue 3, 2013, Pages 467-478

  Briggs, James A ^a   Sun, Jane ^a   Shepherd, Jill ^a   Ovchinnikov, Dmitry A ^a   Chung, Tung Liang ^a   Nayler, Sam P ^a   Kao, Li Pin ^a   Morrow, Carl A ^a   Thakar, Nilay Y ^a   Soo, Set Yen ^b   Peura, Teija ^b   Grimmond, Sean ^a   Wolvetang, Ernst J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b StemCore   (Australia)

Author keywords

Disease modeling; Down syndrome; Gene dosage; Induced pluripotent stem cells; Neural development; Trisomy 21

Indexed keywords

ACETYLCYSTEINE;

APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL LINEAGE; CELL PROLIFERATION; CHROMOSOME 21; CONTROLLED STUDY; DOWN SYNDROME; GENE DOSAGE; GENE OVEREXPRESSION; GLIA CELL; HUMAN; HUMAN CELL; NERVE CELL DIFFERENTIATION; NERVE FIBER; NEURITE; OXIDATIVE STRESS; PHENOTYPE; PLURIPOTENT STEM CELL; TRISOMY 21;

CELL DIFFERENTIATION; DOWN SYNDROME; FEMALE; GENE DOSAGE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MALE; NEURITES; NEUROGENESIS; NEURONS; TRANSCRIPTOME;

EID: 84874913500     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.1297     Document Type: Article

References (50)

1. Parker SE, Mai CT, Canfield MA et al. Updated National Birth Prevalence estimates for selected birth defects in the United States, 2004-2006. Birth Defects Res A Clin Mol Teratol 2010;88: 1008-1016.
2. Pennington BF, Moon J, Edgin J et al. The neuropsychology of Down syndrome: Evidence for hippocampal dysfunction. Child Dev 2003;74: 75-93.
3. Chapman RS, Hesketh LJ.Behavioral phenotype of individuals with Down syndrome. Ment Retard Dev Disabil Res Rev 2000;6: 84-95.
4. Lejeune J, Turpin R, Gautier M.Mongolism; a chromosomal disease (trisomy). Bull Acad Natl Med 1959;143: 256-265.
5. Roper RJ, Reeves RH.Understanding the basis for Down syndrome phenotypes. Plos Genet 2006;2:e50.
6. Rachidi M, Lopes C.Mental retardation and associated neurological dysfunctions in Down syndrome: A consequence of dysregulation in critical chromosome 21 genes and associated molecular pathways. Eur J Paediatr Neurol 2008;12: 168-182.
7. Takashima S, Iida K, Mito T et al. Dendritic and histochemical development and ageing in patients with Down's syndrome. J Intellect Disabil Res 1994;38(pt 3): 265-273.
8. Becker LE, Armstrong DL, Chan F.Dendritic atrophy in children with Down's syndrome. Ann Neurol 1986;20: 520-526.
9. Zdaniuk G, Wierzba-Bobrowicz T, Szpak GM et al. Astroglia disturbances during development of the central nervous system in fetuses with Down's syndrome. Folia Neuropathol 2011;49: 109-114.
10. Mito T, Becker LE.Developmental changes of S-100 protein and glial fibrillary acidic protein in the brain in Down syndrome. Exp Neurol 1993;120: 170-176.
11. Lu J, Esposito G, Scuderi C et al. S100B and APP promote a gliocentric shift and impaired neurogenesis in Down syndrome neural progenitors. PLoS One 2011;6:e22126.
12. Schmidt-Sidor B, Wisniewski KE, Shepard TH et al. Brain growth in Down syndrome subjects 15 to 22 weeks of gestational age and birth to 60 months. Clin Neuropathol 1990;9: 181-190.
13. Guidi S, Ciani E, Bonasoni P et al. Widespread proliferation impairment and hypocellularity in the cerebellum of fetuses with down syndrome. Brain Pathol 2011;21: 361-373.
14. Contestabile A, Fila T, Ceccarelli C et al. Cell cycle alteration and decreased cell proliferation in the hippocampal dentate gyrus and in the neocortical germinal matrix of fetuses with Down syndrome and in Ts65Dn mice. Hippocampus 2007;17: 665-678.
15. Guidi S, Bonasoni P, Ceccarelli C et al. Neurogenesis impairment and increased cell death reduce total neuron number in the hippocampal region of fetuses with Down syndrome. Brain Pathol 2008;18: 180-197.
16. Busciglio J, Yankner BA. Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Nature 1995;378: 776-779.
17. Helguera P, Pelsman A, Pigino G et al. ets-2 promotes the activation of a mitochondrial death pathway in Down's syndrome neurons. J Neurosci 2005;25: 2295-2303.
18. Korbel JO, Tirosh-Wagner T, Urban AE et al. The genetic architecture of Down syndrome phenotypes revealed by high-resolution analysis of human segmental trisomies. Proc Natl Acad Sci USA 2009;106: 12031-12036.
19. Lyle R, Bena F, Gagos S et al. Genotype-phenotype correlations in Down syndrome identified by array CGH in 30 cases of partial trisomy and partial monosomy chromosome 21. Eur J Hum Genet 2009; 17: 454-466.
20. Haydar TF, Reeves RH.Trisomy 21 and early brain development. Trends Neurosci 2012;35: 81-91.
21. Reeves RH.Down syndrome mouse models are looking up. Trends Mol Med 2006;12: 237-240.
22. Watase K, Zoghbi HY.Modelling brain diseases in mice: The challenges of design and analysis. Nat Rev Genet 2003;4: 296-307.
23. O'Doherty A, Ruf S, Mulligan C et al. An aneuploid mouse strain carrying human chromosome 21 with Down syndrome phenotypes. Science 2005;309: 2033-2037.
24. Yu T, Li Z, Jia Z et al. A mouse model of Down syndrome trisomic for all human chromosome 21 syntenic regions. Hum Mol Genet 2010;19: 2780-2791.
25. Gardiner K, Fortna A, Bechtel L et al. Mouse models of Down syndrome: How useful can they be? Comparison of the gene content of human chromosome 21 with orthologous mouse genomic regions. Gene 2003;318: 137-147.
26. Grskovic M, Javaherian A, Strulovici B et al. Induced pluripotent stem cells - Opportunities for disease modelling and drug discovery. Nat Rev Drug Discov 2011;10: 915-929.
27. Zhu H, Lensch MW, Cahan P et al. Investigating monogenic and complex diseases with pluripotent stem cells. Nat Rev Genet 2011;12: 266-275.
28. Xu RH, Peck RM, Li DS et al. Basic FGF and suppression of BMP signaling sustain undifferentiated proliferation of human ES cells. Nat Methods 2005;2: 185-190.
29. Yu J, Hu K, Smuga-Otto K et al. Human induced pluripotent stem cells free of vector and transgene sequences. Science 2009;324: 797-801.
30. Chambers SM, Fasano CA, Papapetrou EP et al. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol 2009;27: 275-280.
31. Kim DS, Lee JS, Leem JW et al. Robust enhancement of neural differentiation from human ES and iPS cells regardless of their innate difference in differentiation propensity. Stem Cell Rev 2010;6: 270-281.
32. Laslett AL, Grimmond S, Gardiner B et al. Transcriptional analysis of early lineage commitment in human embryonic stem cells. BMC Dev Biol 2007;7: 12.
33. Livak KJ, Schmittgen TD.Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25: 402-408.
34. Blankenberg D, Von Kuster G, Coraor N et al. Galaxy: A web-based genome analysis tool for experimentalists. Curr Protoc Mol Biol 2010; Chapter 19:Unit 19.10.11-21.
35. Goecks J, Nekrutenko A, Taylor J.Galaxy: A comprehensive approach for supporting accessible, reproducible, and transparent computational research in the life sciences. Genome Biol 2010;11:R86.
36. Smyth GK, Speed T.Normalization of cDNA microarray data. Methods 2003;31: 265-273.
37. Mao R, Zielke CL, Zielke HR et al. Global up-regulation of chromosome 21 gene expression in the developing Down syndrome brain. Genomics 2003;81: 457-467.
38. Mao R, Wang X, Spitznagel EL, Jr.et al. Primary and secondary transcriptional effects in the developing human Down syndrome brain and heart. Genome Biol 2005;6:R107.
39. FitzPatrick DR, Ramsay J, McGill NI et al. Transcriptome analysis of human autosomal trisomy. Hum Mol Genet 2002;11: 3249-3256.
40. Lockstone HE, Harris LW, Swatton JE et al. Gene expression profiling in the adult Down syndrome brain. Genomics 2007;90: 647-660.
41. Ait Yahya-Graison E, Aubert J, Dauphinot L et al. Classification of human chromosome 21 gene-expression variations in Down syndrome: Impact on disease phenotypes. Am J Hum Genet 2007;81: 475-491.
42. Dauphinot L, Lyle R, Rivals I et al. The cerebellar transcriptome during postnatal development of the Ts1Cje mouse, a segmental trisomy model for Down syndrome. Hum Mol Genet 2005;14: 373-384.
43. Saran NG, Pletcher MT, Natale JE et al. Global disruption of the cerebellar transcriptome in a Down syndrome mouse model. Hum Mol Genet 2003;12: 2013-2019.
44. Kahlem P, Sultan M, Herwig R et al. Transcript level alterations reflect gene dosage effects across multiple tissues in a mouse model of down syndrome. Genome Res 2004;14: 1258-1267.
45. Bhattacharyya A, McMillan E, Chen SI et al. A critical period in cortical interneuron neurogenesis in down syndrome revealed by human neural progenitor cells. Dev Neurosci 2009;31: 497-510.
46. Miller FD, Gauthier AS.Timing is everything: Making neurons versus glia in the developing cortex. Neuron 2007;54: 357-369.
47. Burger PC, Vogel FS.The development of the pathologic changes of Alzheimer's disease and senile dementia in patients with Down's syndrome. Am J Pathol 1973;73: 457-476.
48. Shi Y, Kirwan P, Smith J et al. A human stem cell model of early Alzheimer's disease pathology in Down syndrome. Sci Transl Med 2012;4.
49. Wolvetang EJ, Bradfield OM, Hatzistavrou T et al. Overexpression of the chromosome 21 transcription factor Ets2 induces neuronal apoptosis. Neurobiol Dis 2003;14: 349-356.
50. Wolvetang EJ, Wilson TJ, Sanij E et al. ETS2 overexpression in transgenic models and in Down syndrome predisposes to apoptosis via the p53 pathway. Hum Mol Genet 2003;12: 247-255.